含有少量腺癌成分的肺鳞状细胞癌(SQCC-mGC)基因突变分析  

Comprehensive analysis of oncogenic mutations 1 in lung squamous cell carcinoma with minor glandular component( SQCC-mGC)

作　　者：惠文涛[1] 姜建涛[1] 马小斌[1] 昝瑛[1] 黄珊[1] 

机构地区：[1]西安交通大学第二附属医院肿瘤科,陕西西安710004

出　　处：《现代肿瘤医学》2015年第14期1988-1989,共2页Journal of Modern Oncology

基　　金：陕西省社发公关项目(编号:2009k12-01)

摘　　要：目的:检测SQCC-m GC中的致癌基因突变,以期指导肺鳞癌靶向治疗患者的筛选。方法:用HRM技术检测100例病理确诊的肺鳞癌标本中肺癌驱动基因。结果:与单纯SQCC组相比,SQCC-m GC组带有已知致癌基因突变的比例更高(23.3%vs 4.3%),差异具有统计学意义(P<0.001)。结论:EGFR、ALK或KRAS基因突变在SQCC-m GC中出现频率较高,在治疗前对SQCC-m GC患者进行致癌基因突变检测,有助于筛选靶向治疗的潜在受益人群。Objective：To detect EGFR,KRAS,ALK gene mutation in patients with contains a small amount of lung squamous cell carcinoma adenocarcinoma component （SQCC-mGC）.Methods：One hundred surgically resected lung squamous cell carcinoma（SQCC） specimens were pathologically subdivided into SQCC group in 70 and SQCC-mGC group in 30.The EGFR,KRAS and ALK gene mutation were detected with HRM.Results：There was a significant difference between SQCC-mGC group and SQCC goup in rate of gene mutations （23.3％ vs 4.3 ％,P ＜ 0.001）.Conclusion：The rate of EGFR,KRAS and ALK gene mutation was remarkably higher in group SQCC-mGC than that of group SQCC.To detect these gene mutation before the initiation of treatment might be benefited to those patients with SQCC-mGC.

关 键 词：基因突变 肺鳞腺状细胞癌 HRM技术 

分 类 号：R734.2[医药卫生—肿瘤]